VolitionRX (VNRX)

• Market cap: $65.5M
• 1 day: 6.68%
• 5 days: 7.76%
• 1 month: 35.91%
• 3 months: 9.24%
• 6 months: 12.53%
• Year to date: 0.92%
• 1 year: -5.81%
• 5 years: -80.96%
• 10 years: -85.11%
• Sector: Healthcare
• Industry: Diagnostics & Research

About: VolitionRX Ltd is a United States-based epigenetics company that applies its Nucleosomics platform through its subsidiaries to develop simple, easy-to-use, cost-effective blood tests to help diagnose and monitor range of life-altering diseases including some cancers and diseases associated with NETosis such as sepsis and COVID-19. The tests are based on the science of Nucleosomics, which is the practice of identifying and measuring nucleosomes in the bloodstream or other bodily fluid - an indication that disease is present. The company is focused on human diagnostics and monitoring but also has a subsidiary focused on animal diagnostics and monitoring.

Employees: 52

Fund manager confidence

Based on 2025 Q1 regulatory disclosures by fund managers ($100M+ AUM)

33% more repeat investments, than reductions

Existing positions increased: 8 | Existing positions reduced: 6

7% more capital invested

Capital invested by funds: $11.2M [Q4 2024] → $12M (+$765K) [Q1 2025]

2.42% more ownership

Funds ownership: 19.47% [Q4 2024] → 21.89% (+2.42%) [Q1 2025]

7% less funds holding

Funds holding: 27 [Q4 2024] → 25 (-2) [Q1 2025]

33% less first-time investments, than exits

New positions opened: 4 | Existing positions closed: 6

Research analyst outlook

3 Wall Street Analysts provided 1 year price targets over the past 3 months

• Low target: $2.50 293% upside
• Avg. target: $3.50 450% upside
• High target: $5 686% upside

3 analyst ratings

• positive: 3 100%
• neutral: 0 0%
• negative: 0 0%

Jones Trading Justin Walsh	372% upside $3	Buy Initiated	10 Jun 2025
D. Boral Capital Jason Kolbert	686% upside $5	Buy Maintained	30 Apr 2025
HC Wainwright & Co. Yi Chen	293% upside $2.50	Buy Reiterated	11 Apr 2025